Envoy Medical to Present at Investor Conferences on June 25th

Rhea-AI Summary

Envoy Medical (NASDAQ: COCH) announced that CEO Brent Lucas will present at two investor events on June 25, 2026.

He will speak at the Life Sciences Virtual Investor Forum at 1:00 p.m. ET and the Biotech Webull Webinar Panel at 2:40 p.m. ET, both accessible via webcast links.

News Market Reaction – COCH

-3.12%

-3.12% Session close to close

In the Jun 18 session, COCH declined 3.12%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026.

Life Sciences Virtual Investor Forum
Dates: June 24^th & 25^th
Presentation Day and Time: Thursday, June 25, 2026, at 1:00 p.m. ET
Webcast Link

Biotech Webull Webinar Panel
Presentation Day and Time: Thursday, June 25, 2026, at 2:40 p.m. ET
Webcast Link

To schedule a meeting with the Envoy Medicals management team, please contact KCSA Strategic Communications at Envoy@kcsa.com.

To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.

About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.

*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.

Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.

Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.

Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301966

FAQ

When will Envoy Medical (NASDAQ: COCH) present at the Life Sciences Virtual Investor Forum?

Envoy Medical will present at the Life Sciences Virtual Investor Forum on Thursday, June 25, 2026, at 1:00 p.m. ET. According to the company, the event is part of a two-day forum on June 24 and 25.

What time is Envoy Medical's Biotech Webull Webinar Panel presentation on June 25, 2026?

Envoy Medical's Biotech Webull Webinar Panel presentation is scheduled for Thursday, June 25, 2026, at 2:40 p.m. ET. According to the company, the session will be available via a webcast link for investors.

Who will represent Envoy Medical (COCH) at the June 25, 2026 investor conferences?

Envoy Medical will be represented by its CEO, Brent Lucas, at both June 25, 2026 investor events. According to the company, he will present at the Life Sciences Virtual Investor Forum and the Biotech Webull Webinar Panel.

How can investors access Envoy Medical's June 25, 2026 investor conference webcasts?

Investors can access Envoy Medical's June 25, 2026 presentations through provided webcast links for each event. According to the company, separate links will be available for the Life Sciences Virtual Investor Forum and the Biotech Webull Webinar Panel.

How can investors schedule a meeting with Envoy Medical's management team around the June 25 events?

Investors can request meetings with Envoy Medical's management by contacting KCSA Strategic Communications at Envoy@kcsa.com. According to the company, this channel is open for arranging discussions around the June 25, 2026 presentations.

How can I join Envoy Medical's (NASDAQ: COCH) email distribution list for investor updates?

Investors can join Envoy Medical's email list by emailing Envoy@kcsa.com with COCH in the subject line. According to the company, this ensures inclusion in future hearing health and investor-related communications.